Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.
Yagi Y, Kanemasa Y, Sasaki Y, Goto S, Yamamura Y, Masuda Y, Fujita K, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Matsuda S, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T.
Yagi Y, et al. Among authors: kobayashi t.
J Clin Exp Hematop. 2024;64(2):107-118. doi: 10.3960/jslrt.24009.
J Clin Exp Hematop. 2024.
PMID: 38925972
Free PMC article.